Trial Outcomes & Findings for A Study to Evaluate Safety and Immunogenicity of One and Two Doses of IMVAMUNE® Smallpox Vaccine in 56-80 Year Old Vaccinia-experienced Subjects (NCT NCT00857493)

NCT ID: NCT00857493

Last Updated: 2019-01-10

Results Overview

Incidence of Serious Adverse Events (SAEs) probably, possibly or definitely related to the trial vaccine

Recruitment status

COMPLETED

Study phase

PHASE2

Target enrollment

120 participants

Primary outcome timeframe

within 8 weeks

Results posted on

2019-01-10

Participant Flow

Participant milestones

Participant milestones
Measure
Group 1
IMVAMUNE: Two s.c. vaccinations with 0.5 ml IMVAMUNE® vaccine containing 1 x 10E8 TCID50 / dose
Group 2
IMVAMUNE: One s.c. vaccination with placebo (0.5 ml saline), followed by a second s.c. vaccination with 0.5 ml IMVAMUNE® vaccine containing 1 x 10E8 TCID50
Overall Study
STARTED
62
58
Overall Study
COMPLETED
59
58
Overall Study
NOT COMPLETED
3
0

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

A Study to Evaluate Safety and Immunogenicity of One and Two Doses of IMVAMUNE® Smallpox Vaccine in 56-80 Year Old Vaccinia-experienced Subjects

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Group 1
n=62 Participants
IMVAMUNE: Two s.c. vaccinations with 0.5 ml IMVAMUNE® vaccine containing 1 x 10E8 TCID50 / dose
Group 2
n=58 Participants
IMVAMUNE: One s.c. vaccination with placebo (0.5 ml saline), followed by a second s.c. vaccination with 0.5 ml IMVAMUNE® vaccine containing 1 x 10E8 TCID50
Total
n=120 Participants
Total of all reporting groups
Age, Continuous
64.6 years
STANDARD_DEVIATION 5.41 • n=5 Participants
62.6 years
STANDARD_DEVIATION 5.85 • n=7 Participants
63.7 years
STANDARD_DEVIATION 5.70 • n=5 Participants
Sex: Female, Male
Female
37 Participants
n=5 Participants
40 Participants
n=7 Participants
77 Participants
n=5 Participants
Sex: Female, Male
Male
25 Participants
n=5 Participants
18 Participants
n=7 Participants
43 Participants
n=5 Participants

PRIMARY outcome

Timeframe: within 8 weeks

Population: Safety Analysis Set

Incidence of Serious Adverse Events (SAEs) probably, possibly or definitely related to the trial vaccine

Outcome measures

Outcome measures
Measure
Group 1
n=62 Participants
IMVAMUNE: Two s.c. vaccinations with 0.5 ml IMVAMUNE® vaccine containing 1 x 10E8 TCID50 / dose
Group 2
n=58 Participants
IMVAMUNE: One s.c. vaccination with placebo (0.5 ml saline), followed by a second s.c. vaccination with 0.5 ml IMVAMUNE® vaccine containing 1 x 10E8 TCID50
Related Serious Adverse Events
0 Participants
0 Participants

SECONDARY outcome

Timeframe: within 29 days after any vaccination

Population: Safety Analysis Set

Occurrence of unsolicited non-serious AEs by Intensity

Outcome measures

Outcome measures
Measure
Group 1
n=62 Participants
IMVAMUNE: Two s.c. vaccinations with 0.5 ml IMVAMUNE® vaccine containing 1 x 10E8 TCID50 / dose
Group 2
n=58 Participants
IMVAMUNE: One s.c. vaccination with placebo (0.5 ml saline), followed by a second s.c. vaccination with 0.5 ml IMVAMUNE® vaccine containing 1 x 10E8 TCID50
Unsolicited Non-serious AEs: Intensity
Missing
0 events
0 events
Unsolicited Non-serious AEs: Intensity
Total
73 events
58 events
Unsolicited Non-serious AEs: Intensity
Grade 1
60 events
50 events
Unsolicited Non-serious AEs: Intensity
Grade 2
9 events
7 events
Unsolicited Non-serious AEs: Intensity
Grade 3
4 events
1 events
Unsolicited Non-serious AEs: Intensity
Grade 4
0 events
0 events

SECONDARY outcome

Timeframe: within 29 days after any vaccination

Population: Safety Analysis Set

Occurrence of unsolicited non-serious AEs by relationship to study vaccine

Outcome measures

Outcome measures
Measure
Group 1
n=62 Participants
IMVAMUNE: Two s.c. vaccinations with 0.5 ml IMVAMUNE® vaccine containing 1 x 10E8 TCID50 / dose
Group 2
n=58 Participants
IMVAMUNE: One s.c. vaccination with placebo (0.5 ml saline), followed by a second s.c. vaccination with 0.5 ml IMVAMUNE® vaccine containing 1 x 10E8 TCID50
Unsolicited Non-serious AEs: Relationship to Vaccination
Unrelated/None
32 events
26 events
Unsolicited Non-serious AEs: Relationship to Vaccination
Unlikely
6 events
2 events
Unsolicited Non-serious AEs: Relationship to Vaccination
Possible
20 events
13 events
Unsolicited Non-serious AEs: Relationship to Vaccination
Probable
8 events
5 events
Unsolicited Non-serious AEs: Relationship to Vaccination
Definite
7 events
12 events
Unsolicited Non-serious AEs: Relationship to Vaccination
Missing
0 events
0 events
Unsolicited Non-serious AEs: Relationship to Vaccination
Total
73 events
58 events

SECONDARY outcome

Timeframe: within 29 days after any vaccination

Population: Safety Analysis Set

Incidence of any Grade \>=3 Adverse Events probably, possibly or definitely related to the trial vaccine. Pooled solicited (general) and unsolicited AEs

Outcome measures

Outcome measures
Measure
Group 1
n=62 Participants
IMVAMUNE: Two s.c. vaccinations with 0.5 ml IMVAMUNE® vaccine containing 1 x 10E8 TCID50 / dose
Group 2
n=58 Participants
IMVAMUNE: One s.c. vaccination with placebo (0.5 ml saline), followed by a second s.c. vaccination with 0.5 ml IMVAMUNE® vaccine containing 1 x 10E8 TCID50
Related Grade >=3 Adverse Events
3 Participants
1 Participants

SECONDARY outcome

Timeframe: within 32 weeks

Population: Safety Analysis Set

Incidence, relationship and intensity of any cardiac sign or symptom indicating a case of myo-/pericarditis (AESI). AESIs were defined as any cardiac symptoms and ECG changes determined to be clinically significant or cardiac enzymes elevated above 2 x upper limit of normal range (ULN).

Outcome measures

Outcome measures
Measure
Group 1
n=62 Participants
IMVAMUNE: Two s.c. vaccinations with 0.5 ml IMVAMUNE® vaccine containing 1 x 10E8 TCID50 / dose
Group 2
n=58 Participants
IMVAMUNE: One s.c. vaccination with placebo (0.5 ml saline), followed by a second s.c. vaccination with 0.5 ml IMVAMUNE® vaccine containing 1 x 10E8 TCID50
Cardiac Signs or Symptoms
Any AESI
5 Participants
0 Participants
Cardiac Signs or Symptoms
Any AESI with intensity >= Grade 3
0 Participants
0 Participants
Cardiac Signs or Symptoms
Any AESI assessed as related to vaccine
0 Participants
0 Participants

SECONDARY outcome

Timeframe: within 8 days after any vaccination

Population: Safety Analysis Set

Incidence and intensity of solicited local AEs (pain, erythema, swelling, induration, and pruritus). Percentages based on subjects with at least one completed diary card.

Outcome measures

Outcome measures
Measure
Group 1
n=62 Participants
IMVAMUNE: Two s.c. vaccinations with 0.5 ml IMVAMUNE® vaccine containing 1 x 10E8 TCID50 / dose
Group 2
n=58 Participants
IMVAMUNE: One s.c. vaccination with placebo (0.5 ml saline), followed by a second s.c. vaccination with 0.5 ml IMVAMUNE® vaccine containing 1 x 10E8 TCID50
Solicited Local Adverse Events
Pain: Grade >=3
4 Participants
1 Participants
Solicited Local Adverse Events
Erythema: Any
49 Participants
37 Participants
Solicited Local Adverse Events
Erythema: Grade >=3
3 Participants
1 Participants
Solicited Local Adverse Events
Pain: Any
46 Participants
36 Participants
Solicited Local Adverse Events
Swelling: Any
39 Participants
27 Participants
Solicited Local Adverse Events
Swelling: Grade >=3
0 Participants
0 Participants
Solicited Local Adverse Events
Induration: Any
31 Participants
17 Participants
Solicited Local Adverse Events
Induration: Grade >=3
0 Participants
0 Participants
Solicited Local Adverse Events
Pruritis: Any
27 Participants
22 Participants
Solicited Local Adverse Events
Pruritis: Grade >=3
0 Participants
0 Participants

SECONDARY outcome

Timeframe: within 8 days after any vaccination

Population: Safety Analysis Set

Incidence of solicited general AEs (body temperature increased, headache, myalgia, chills, nausea, and fatigue): Intensity and relationship tovaccination. Percentages based on subjects with at least one completed diary card.

Outcome measures

Outcome measures
Measure
Group 1
n=62 Participants
IMVAMUNE: Two s.c. vaccinations with 0.5 ml IMVAMUNE® vaccine containing 1 x 10E8 TCID50 / dose
Group 2
n=58 Participants
IMVAMUNE: One s.c. vaccination with placebo (0.5 ml saline), followed by a second s.c. vaccination with 0.5 ml IMVAMUNE® vaccine containing 1 x 10E8 TCID50
Solicited General Adverse Events
Nausea: Related
4 Participants
4 Participants
Solicited General Adverse Events
Nausea: Grade >=3
0 Participants
0 Participants
Solicited General Adverse Events
Increased body temperature: Any
2 Participants
1 Participants
Solicited General Adverse Events
Increased body temperature: Related
2 Participants
0 Participants
Solicited General Adverse Events
Increased body temperature: Grade >=3
0 Participants
0 Participants
Solicited General Adverse Events
Headache: Any
19 Participants
22 Participants
Solicited General Adverse Events
Headache: Related
15 Participants
14 Participants
Solicited General Adverse Events
Headache: Grade >=3
1 Participants
0 Participants
Solicited General Adverse Events
Myalgia: Any
19 Participants
14 Participants
Solicited General Adverse Events
Myalgia: Related
14 Participants
12 Participants
Solicited General Adverse Events
Myalgia: Grade >=3
2 Participants
1 Participants
Solicited General Adverse Events
Chills: Any
5 Participants
4 Participants
Solicited General Adverse Events
Chills: Related
5 Participants
1 Participants
Solicited General Adverse Events
Chills: Grade >=3
0 Participants
0 Participants
Solicited General Adverse Events
Nausea: Any
7 Participants
5 Participants
Solicited General Adverse Events
Fatigue: Any
21 Participants
18 Participants
Solicited General Adverse Events
Fatigue: Related
18 Participants
15 Participants
Solicited General Adverse Events
Fatigue: Grade >=3
1 Participants
0 Participants

SECONDARY outcome

Timeframe: within 32 weeks

Population: Full Analysis Set

Response rate based on vaccinia-specific Enzyme-linked Immunosorbent Assay (ELISA). Response is defined as the appearance of antibody titers ≥ detection limit (50) for initially seronegative subjects, or an increase of the antibody titer compared to Baseline titer for initially seropositive subjects. Individual peak response rate is based on the maximum post-Baseline antibody titer within 8 weeks (end of active trial phase). Percentages based on number of subjects with data available.

Outcome measures

Outcome measures
Measure
Group 1
n=61 Participants
IMVAMUNE: Two s.c. vaccinations with 0.5 ml IMVAMUNE® vaccine containing 1 x 10E8 TCID50 / dose
Group 2
n=58 Participants
IMVAMUNE: One s.c. vaccination with placebo (0.5 ml saline), followed by a second s.c. vaccination with 0.5 ml IMVAMUNE® vaccine containing 1 x 10E8 TCID50
ELISA Response Rate
Week 6
98.3 percentage of subjects
Interval 91.1 to 100.0
96.6 percentage of subjects
Interval 88.1 to 99.6
ELISA Response Rate
Week 8
100.0 percentage of subjects
Interval 93.9 to 100.0
100.0 percentage of subjects
Interval 93.8 to 100.0
ELISA Response Rate
Individual Peak
100.0 percentage of subjects
Interval 94.1 to 100.0
100.0 percentage of subjects
Interval 93.8 to 100.0
ELISA Response Rate
Week 32
94.9 percentage of subjects
Interval 85.9 to 98.9
82.8 percentage of subjects
Interval 70.6 to 91.4
ELISA Response Rate
Week 2
98.4 percentage of subjects
Interval 91.2 to 100.0
19.0 percentage of subjects
Interval 9.9 to 31.4
ELISA Response Rate
Week 4
96.6 percentage of subjects
Interval 88.3 to 99.6
19.0 percentage of subjects
Interval 9.9 to 31.4

SECONDARY outcome

Timeframe: within 32 weeks

Population: Full Analysis Set

Seroconversion rate based on vaccinia-specific Enzyme-linked Immunosorbent Assay (ELISA). Seroconversion is defined as the appearance of antibody titers ≥ detection limit (50) for initially seronegative subjects, or a doubling or more of the antibody titer compared to Baseline titer for initially seropositive subjects. Individual peak seroconversion rate is based on the maximum post-Baseline antibody titer within 8 weeks (end of active trial phase). Percentages based on number of subjects with data available.

Outcome measures

Outcome measures
Measure
Group 1
n=61 Participants
IMVAMUNE: Two s.c. vaccinations with 0.5 ml IMVAMUNE® vaccine containing 1 x 10E8 TCID50 / dose
Group 2
n=58 Participants
IMVAMUNE: One s.c. vaccination with placebo (0.5 ml saline), followed by a second s.c. vaccination with 0.5 ml IMVAMUNE® vaccine containing 1 x 10E8 TCID50
ELISA Seroconversion Rate
Week 32
59.3 percentage of subjects
Interval 45.7 to 71.9
58.6 percentage of subjects
Interval 44.9 to 71.4
ELISA Seroconversion Rate
Week 8
83.1 percentage of subjects
Interval 71.0 to 91.6
77.6 percentage of subjects
Interval 64.7 to 87.5
ELISA Seroconversion Rate
Individual Peak
90.2 percentage of subjects
Interval 79.8 to 96.3
84.5 percentage of subjects
Interval 72.6 to 92.7
ELISA Seroconversion Rate
Week 2
83.6 percentage of subjects
Interval 71.9 to 91.8
1.7 percentage of subjects
Interval 0.0 to 9.2
ELISA Seroconversion Rate
Week 4
79.7 percentage of subjects
Interval 67.2 to 89.0
3.4 percentage of subjects
Interval 0.4 to 11.9
ELISA Seroconversion Rate
Week 6
83.3 percentage of subjects
Interval 71.5 to 91.7
82.8 percentage of subjects
Interval 70.6 to 91.4

SECONDARY outcome

Timeframe: within 32 weeks

Population: Full Analysis Set

Geometric Mean Titers (GMT) based on vaccinia-specific Enzyme-linked Immunosorbent Assay (ELISA). Individual peak is defined as the maximum post-Baseline antibody titer within 8 weeks (end of active trial phase). Titers below the detection limit are included with a value of '1'.

Outcome measures

Outcome measures
Measure
Group 1
n=61 Participants
IMVAMUNE: Two s.c. vaccinations with 0.5 ml IMVAMUNE® vaccine containing 1 x 10E8 TCID50 / dose
Group 2
n=58 Participants
IMVAMUNE: One s.c. vaccination with placebo (0.5 ml saline), followed by a second s.c. vaccination with 0.5 ml IMVAMUNE® vaccine containing 1 x 10E8 TCID50
ELISA GMT
Week 0
129.0 Titer
Interval 100.3 to 165.8
105.3 Titer
Interval 71.8 to 154.5
ELISA GMT
Week 2
622.5 Titer
Interval 491.2 to 788.9
98.5 Titer
Interval 64.8 to 150.0
ELISA GMT
Week 4
501.2 Titer
Interval 406.4 to 617.9
101.0 Titer
Interval 66.5 to 153.3
ELISA GMT
Week 6
804.1 Titer
Interval 636.3 to 1016.0
605.8 Titer
Interval 479.6 to 765.2
ELISA GMT
Week 8
720.2 Titer
Interval 577.9 to 897.6
505.0 Titer
Interval 398.2 to 640.3
ELISA GMT
Individual Peak
992.4 Titer
Interval 769.2 to 1280.3
645.2 Titer
Interval 505.0 to 824.3
ELISA GMT
Week 32
344.6 Titer
Interval 288.9 to 411.1
258.1 Titer
Interval 202.5 to 328.9

SECONDARY outcome

Timeframe: within 32 weeks

Population: Full Analysis Set

Response rate based on vaccinia-specific Plaque Reduction Neutralization Test (PRNT). Response is defined as the appearance of antibody titers ≥ detection limit (15) for initially seronegative subjects, or an increase of the antibody titer compared to Baseline titer for initially seropositive subjects. Individual peak response rate is based on the maximum post-Baseline antibody titer within 8 weeks (end of active trial phase). Percentages based on number of subjects with data available.

Outcome measures

Outcome measures
Measure
Group 1
n=61 Participants
IMVAMUNE: Two s.c. vaccinations with 0.5 ml IMVAMUNE® vaccine containing 1 x 10E8 TCID50 / dose
Group 2
n=58 Participants
IMVAMUNE: One s.c. vaccination with placebo (0.5 ml saline), followed by a second s.c. vaccination with 0.5 ml IMVAMUNE® vaccine containing 1 x 10E8 TCID50
PRNT Response Rate
Week 2
83.6 percentage of subjects
Interval 71.9 to 91.8
15.5 percentage of subjects
Interval 7.3 to 27.4
PRNT Response Rate
Week 4
81.4 percentage of subjects
Interval 69.1 to 90.3
10.3 percentage of subjects
Interval 3.9 to 21.2
PRNT Response Rate
Week 6
96.7 percentage of subjects
Interval 88.5 to 99.6
82.8 percentage of subjects
Interval 70.6 to 91.4
PRNT Response Rate
Week 8
89.8 percentage of subjects
Interval 79.2 to 96.2
79.3 percentage of subjects
Interval 66.6 to 88.8
PRNT Response Rate
Individual Peak
96.7 percentage of subjects
Interval 88.7 to 99.6
84.5 percentage of subjects
Interval 72.6 to 92.7
PRNT Response Rate
Week 32
66.1 percentage of subjects
Interval 52.6 to 77.9
50.0 percentage of subjects
Interval 36.6 to 63.4

SECONDARY outcome

Timeframe: within 32 weeks

Population: Full Analysis Set

Seroconversion rate based on vaccinia-specific Plaque Reduction Neutralization Test (PRNT). Seroconversion is defined as the appearance of antibody titers ≥ detection limit (15) for initially seronegative subjects, or a doubling or more of the antibody titer compared to Baseline titer for initially seropositive subjects. Individual peak seroconversion rate is based on the maximum post-Baseline antibody titer within 8 weeks (end of active trial phase). Percentages based on number of subjects with data available.

Outcome measures

Outcome measures
Measure
Group 1
n=61 Participants
IMVAMUNE: Two s.c. vaccinations with 0.5 ml IMVAMUNE® vaccine containing 1 x 10E8 TCID50 / dose
Group 2
n=58 Participants
IMVAMUNE: One s.c. vaccination with placebo (0.5 ml saline), followed by a second s.c. vaccination with 0.5 ml IMVAMUNE® vaccine containing 1 x 10E8 TCID50
PRNT Seroconversion Rate
Week 2
73.8 percentage of subjects
Interval 60.9 to 84.2
10.3 percentage of subjects
Interval 3.9 to 21.2
PRNT Seroconversion Rate
Week 4
71.2 percentage of subjects
Interval 57.9 to 82.2
8.6 percentage of subjects
Interval 2.9 to 19.0
PRNT Seroconversion Rate
Week 6
90.0 percentage of subjects
Interval 79.5 to 96.2
77.6 percentage of subjects
Interval 64.7 to 87.5
PRNT Seroconversion Rate
Week 8
86.4 percentage of subjects
Interval 75.0 to 94.0
74.1 percentage of subjects
Interval 61.0 to 84.7
PRNT Seroconversion Rate
Individual Peak
95.1 percentage of subjects
Interval 86.3 to 99.0
77.6 percentage of subjects
Interval 64.7 to 87.5
PRNT Seroconversion Rate
Week 32
55.9 percentage of subjects
Interval 42.4 to 68.8
41.4 percentage of subjects
Interval 28.6 to 55.1

SECONDARY outcome

Timeframe: within 32 weeks

Population: Full Analysis Set

Geometric Mean Titers (GMT) based on vaccinia-specific Plaque Reduction Neutralization Test (PRNT). Individual peak is defined as the maximum post-Baseline antibody titer within 8 weeks (end of active trial phase). Titers below the detection limit are included with a value of '1'.

Outcome measures

Outcome measures
Measure
Group 1
n=61 Participants
IMVAMUNE: Two s.c. vaccinations with 0.5 ml IMVAMUNE® vaccine containing 1 x 10E8 TCID50 / dose
Group 2
n=58 Participants
IMVAMUNE: One s.c. vaccination with placebo (0.5 ml saline), followed by a second s.c. vaccination with 0.5 ml IMVAMUNE® vaccine containing 1 x 10E8 TCID50
PRNT GMT
Week 0
11.9 Titer
Interval 7.4 to 19.1
11.3 Titer
Interval 6.5 to 19.4
PRNT GMT
Week 2
111.4 Titer
Interval 72.0 to 172.2
9.2 Titer
Interval 5.3 to 15.8
PRNT GMT
Week 4
79.5 Titer
Interval 52.1 to 121.3
11.3 Titer
Interval 6.8 to 18.7
PRNT GMT
Week 6
210.3 Titer
Interval 146.1 to 302.7
126.7 Titer
Interval 82.4 to 194.8
PRNT GMT
Week 8
144.9 Titer
Interval 96.1 to 218.6
99.5 Titer
Interval 63.8 to 155.1
PRNT GMT
Individual Peak
257.6 Titer
Interval 178.6 to 371.5
139.6 Titer
Interval 89.2 to 218.5
PRNT GMT
Week 32
47.0 Titer
Interval 31.1 to 71.1
27.6 Titer
Interval 17.0 to 44.8

SECONDARY outcome

Timeframe: within 32 weeks

Population: Full Analysis Set

Pearson Correlation Coefficient between the log10 transformed PRNT titers and the log10 transformed ELISA titers

Outcome measures

Outcome measures
Measure
Group 1
n=61 Participants
IMVAMUNE: Two s.c. vaccinations with 0.5 ml IMVAMUNE® vaccine containing 1 x 10E8 TCID50 / dose
Group 2
n=58 Participants
IMVAMUNE: One s.c. vaccination with placebo (0.5 ml saline), followed by a second s.c. vaccination with 0.5 ml IMVAMUNE® vaccine containing 1 x 10E8 TCID50
Correlation PRNT vs ELISA Titers
Week 2
0.704 Pearson correlation coefficient
Interval 0.546 to 0.81
0.489 Pearson correlation coefficient
Interval 0.261 to 0.661
Correlation PRNT vs ELISA Titers
Week 4
0.569 Pearson correlation coefficient
Interval 0.362 to 0.718
0.492 Pearson correlation coefficient
Interval 0.264 to 0.664
Correlation PRNT vs ELISA Titers
Week 6
0.660 Pearson correlation coefficient
Interval 0.484 to 0.781
0.697 Pearson correlation coefficient
Interval 0.531 to 0.808
Correlation PRNT vs ELISA Titers
Week 8
0.600 Pearson correlation coefficient
Interval 0.402 to 0.74
0.616 Pearson correlation coefficient
Interval 0.421 to 0.752
Correlation PRNT vs ELISA Titers
Week 32
0.500 Pearson correlation coefficient
Interval 0.276 to 0.668
0.654 Pearson correlation coefficient
Interval 0.472 to 0.778

Adverse Events

Group 1

Serious events: 2 serious events
Other events: 21 other events
Deaths: 0 deaths

Group 2

Serious events: 2 serious events
Other events: 21 other events
Deaths: 0 deaths

Serious adverse events

Serious adverse events
Measure
Group 1
n=62 participants at risk
IMVAMUNE: Two s.c. vaccinations with 0.5 ml IMVAMUNE® vaccine containing 1 x 10E8 TCID50 / dose
Group 2
n=58 participants at risk
IMVAMUNE: One s.c. vaccination with placebo (0.5 ml saline), followed by a second s.c. vaccination with 0.5 ml IMVAMUNE® vaccine containing 1 x 10E8 TCID50
Infections and infestations
Cellulitis
1.6%
1/62
0.00%
0/58
General disorders
Non-cardiac chest pain
1.6%
1/62
0.00%
0/58
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Prostate cancer
0.00%
0/62
3.4%
2/58

Other adverse events

Other adverse events
Measure
Group 1
n=62 participants at risk
IMVAMUNE: Two s.c. vaccinations with 0.5 ml IMVAMUNE® vaccine containing 1 x 10E8 TCID50 / dose
Group 2
n=58 participants at risk
IMVAMUNE: One s.c. vaccination with placebo (0.5 ml saline), followed by a second s.c. vaccination with 0.5 ml IMVAMUNE® vaccine containing 1 x 10E8 TCID50
Gastrointestinal disorders
Diarrhoea
1.6%
1/62
5.2%
3/58
General disorders
Application site haematoma
0.00%
0/62
5.2%
3/58
General disorders
Injection site haematoma
1.6%
1/62
8.6%
5/58
General disorders
Injection site nodule
6.5%
4/62
3.4%
2/58
General disorders
Injection site pain
3.2%
2/62
0.00%
0/58
Infections and infestations
Nasopharyngitis
3.2%
2/62
1.7%
1/58
Infections and infestations
Sinusitis
4.8%
3/62
0.00%
0/58
Infections and infestations
Upper respiratory tract infection
4.8%
3/62
3.4%
2/58
Injury, poisoning and procedural complications
Contusion
0.00%
0/62
3.4%
2/58
Investigations
Alanine aminotransferase increased
3.2%
2/62
1.7%
1/58
Investigations
Lymphocyte count decreased
3.2%
2/62
0.00%
0/58
Investigations
Neutrophil count decreased
1.6%
1/62
6.9%
4/58
Musculoskeletal and connective tissue disorders
Arthralgia
1.6%
1/62
3.4%
2/58
Nervous system disorders
Dizziness
4.8%
3/62
1.7%
1/58

Additional Information

Program Lead, Clinical Operations

Bavarian Nordic A/S

Phone: +45 3326

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place